• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌和卵巢癌基因检测的当前观点:口服避孕药的决策

A current perspective on genetic testing for breast and ovarian cancer: the oral contraceptive decision.

作者信息

Friedenson B

机构信息

Department of Biochemistry and Molecular Biology at the University of Illinois at Chicago, Chicago, Illinois, USA.

出版信息

MedGenMed. 2001 Nov 2;3(6):2.

PMID:11965197
Abstract

A clinician faces a problem in how best to counsel the woman with a family history of breast or ovarian cancer about her options for pregnancy prevention. The physician must guide her as she makes new and complex decisions. Recent data strongly support an amplified effect of the estrogens in oral contraceptives for the woman with a genetic risk for breast cancer. Nonetheless, a woman's immediate need to prevent pregnancy may be much more important to her than worrying about the long-term risk of breast cancer. Another factor is that oral contraceptives prevent ovarian cancer, so the physician may wish to prescribe them to protect her from ovarian cancer. In some genetic backgrounds, however, oral contraceptives not only do not prevent ovarian cancer, but they may raise the risk of breast cancer so significantly that they should not be taken. With other genetic backgrounds, oral contraceptives will protect the woman from ovarian cancer without much effect on her breast cancer risk. When does each of these cancer risks or benefits become significant? The clinician can provide an important benefit to a woman who must prevent pregnancy yet worries about her cancer risk. The physician can help her evaluate the evidence, with its gaps and uncertainties, in the context of her own preferences. To assist in this evaluation, this decision aid provides base-line estimates of the cancer risk that accompanies each of a woman's options. In some cases, genetic testing is likely to provide valuable information as she makes choices about contraception and the risks vs. benefits of different alternatives available to her.

摘要

临床医生在如何最好地为有乳腺癌或卵巢癌家族史的女性提供预防妊娠的建议方面面临一个问题。在她做出新的复杂决定时,医生必须给予指导。最近的数据有力地支持了口服避孕药中的雌激素对有乳腺癌遗传风险的女性具有放大作用。然而,对一名女性来说,她当下预防妊娠的需求可能比对乳腺癌长期风险的担忧重要得多。另一个因素是口服避孕药可预防卵巢癌,所以医生可能希望开此类药物来保护她免受卵巢癌侵害。然而,在某些遗传背景下,口服避孕药不仅无法预防卵巢癌,反而可能显著提高乳腺癌风险,以至于不应服用。在其他遗传背景下,口服避孕药会保护女性免受卵巢癌侵害,而对其乳腺癌风险影响不大。这些癌症风险或益处何时会变得显著呢?对于必须预防妊娠但又担心癌症风险的女性,临床医生可以提供重要帮助。医生可以在她自身偏好的背景下,帮助她评估证据及其存在的差距和不确定性。为协助这一评估,本决策辅助工具提供了女性每种选择所伴随的癌症风险基线估计。在某些情况下,基因检测在她选择避孕方式以及不同选择的风险与益处时,可能会提供有价值的信息。

相似文献

1
A current perspective on genetic testing for breast and ovarian cancer: the oral contraceptive decision.乳腺癌和卵巢癌基因检测的当前观点:口服避孕药的决策
MedGenMed. 2001 Nov 2;3(6):2.
2
[Clinical and molecular diagnosis of inherited breast-ovarian cancer].遗传性乳腺癌-卵巢癌的临床与分子诊断
J Gynecol Obstet Biol Reprod (Paris). 2003 Apr;32(2):101-19.
3
Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland.波兰BRCA1基因携带者中特定生活方式因素对乳腺癌和卵巢癌风险的影响。
Breast Cancer Res Treat. 2006 Jan;95(2):105-9. doi: 10.1007/s10549-005-9051-5.
4
BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use.乳腺癌1号基因(BRCA1)和乳腺癌2号基因(BRCA2)种系突变与口服避孕药:用还是不用。
Breast. 2005 Aug;14(4):264-8. doi: 10.1016/j.breast.2005.01.005.
5
BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses.BRCA1基因突变及其与卵巢癌的关联:对高级执业护士的启示
J Am Acad Nurse Pract. 2005 Dec;17(12):518-26. doi: 10.1111/j.1745-7599.2005.00091.x.
6
[In cases of familial ovarian cancer, always consider the risk of breast cancer].对于家族性卵巢癌病例,始终要考虑患乳腺癌的风险。
Ned Tijdschr Geneeskd. 2004 Aug 28;148(35):1709-11.
7
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.与BRCA1和BRCA2基因突变相关的遗传性乳腺癌卵巢癌综合征家族中女性接受预防性卵巢切除术后的腹腔内癌转移
Gynecol Oncol. 2005 May;97(2):457-67. doi: 10.1016/j.ygyno.2005.01.039.
8
Reproductive issues for women with BRCA mutations.携带BRCA基因突变女性的生殖问题。
J Natl Cancer Inst Monogr. 2005(34):83-6. doi: 10.1093/jncimonographs/lgi012.
9
Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.接受BRCA1和BRCA2检测的女性临床特征与风险降低干预措施之间的关联:一项单机构研究。
Cancer. 2006 Dec 15;107(12):2745-51. doi: 10.1002/cncr.22352.
10
A survey of preventive measures among BRCA1 mutation carriers from Poland.波兰BRCA1基因变异携带者预防措施的调查。
Clin Genet. 2007 Feb;71(2):153-7. doi: 10.1111/j.1399-0004.2007.00742.x.

引用本文的文献

1
Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers.携带BRCA1/2基因突变女性的癌症风险降低及生殖问题
Fam Cancer. 2008;7(2):179-86. doi: 10.1007/s10689-007-9171-7. Epub 2007 Nov 17.
2
Assessing and managing breast cancer risk: clinical tools for advising patients.评估与管理乳腺癌风险:为患者提供建议的临床工具
MedGenMed. 2004 Jan 14;6(1):8.